Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia

Annals of Internal Medicine

Volumn 133, Issue 11, 2000, Pages 864-876

  Cheng, C H F ^a   Sanders, G D ^a   Hlatky, M A ^a   Heidenreich, P ^a   McDonald, K M ^a   Lee, B K ^a   Larson, M S ^a   Owens, D K ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; METOPROLOL;

ADULT; AGED; ARTICLE; CATHETER ABLATION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ECONOMIC EVALUATION; EMERGENCY WARD; HEALTH CARE COST; HUMAN; HUMAN CELL; HUMAN TISSUE; LIFE EXPECTANCY; PRIORITY JOURNAL; QUALITY OF LIFE; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT OUTCOME;

EID: 0034610316     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-133-11-200012050-00010     Document Type: Article

References (87)

1. Paroxysmal supraventricular tachycardia in the general population
2. Supraventricular tachycardia
3. Quality of life before and after radiofrequency catheter ablation in patients with drug refractory atrioventricular nodal reentrant tachycardia
4. Catheter ablation for cardiac arrhythmias: Clinical applications, personnel and facilities
5. The present role of radiofrequency catheter ablation in the management of cardiac arrhythmias
6. Radiofrequency catheter ablation for cardiac tachyarrhythmias
7. Ablation therapy for cardiac arrhythmias
8. Radiofrequency catherer ablation for patients with supraventricular tachycardia
9. Radio-frequency ablation as treatment for cardiac arrhythmias
10. Safety of slow pathway ablation in patients with atrioventricular node reentrant tachycardia and a long fast pathway effective refractory period
11. Role of radiofrequency ablation in the management of supraventricular arrhythmias: Experience in 760 consecutive patients
12. Radiofrequency catheter ablation for paroxysmal supraventricular tachycardia in children and adolescents without structural heart disease.Pediatric EP Society, Radiofrequency Catheter Ablation Registry
13. Long term results of fast pathway ablation in atrioventricular nodal reentry tachycardia using a modified technique
14. NASPE Survey on Catheter Ablation
15. In-hospital results of radiofrequency ablation of supraventricular tachycardia
16. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: Final results of a prospective, multicenter clinical trial
17. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias
18. The effects of radiofrequency ablation versus medical therapy on the quality-of-life and exercise capacity in patients with accessory pathway-mediated supraventricular tachycardia: A treatment comparison study
19. Complications of radiofrequency catheter ablation: A review
20. Complications of diagnostic dectrophysiologic studies and radiofrequency catheter ablation in patients with tachyarrhythmias: An eight-year survey of 3,966 consecutive procedures in a tertiary referral center
21. Cost of catheter versus surgical ablation in the Wolff-Parkinson-White syndrome
22. Safety and cost of outpatient radiofrequency ablation of the slow pathway in patients with atrioventricular nodal reentrant tachycardia
23. Cost effectiveness of radiofrequency catheter ablation in the treatment of symptomatic supraventricular tachyarrhythmias
24. Comparison of the cost of radiofrequency catheter modification of the atrioventricular node and medical therapy for drug-refractory atrioventricular node reentrant tachycardia
25. Cost-effectiveness of radiofrequency ablation compared with other strategies in Wolff-Parkinson-White syndrome
26. The 1998 NASPE prospective catheter ablation registry
27. Predictors of recurrent atrioventricular nodal reentry after selective slow pathway ablation
28. Recurrence of conduction following radiofrequency catheter ablation procedures: Relationship to ablation target and electrode temperature
29. The Multicentre European Radiofrequency Survey (MERFS): Complications of radiofrequency catheter ablation of arrhythmias
30. Incidence of complete atrioventricular block following attempted radiofrequency catheter modification of the atrioventricular node in 880 patients. Results of the Multicenrer European Radiofrequency Survey (MERFS)
31. Selective radiofrequency catheter ablation of the slow pathway for common and uncommon atrioventricular nodal reentrant tachycardia
32. Treatment of supraventricular tachycardia due to atrioventricular nodal reentry, by radiofrequency catheter ablation of slow-pathway conduction
33. Radiofrequency catheter ablation of accessory pathways: A learning experience
34. Curative percutaneous catheter ablation using radiofrequency energy for accessory pathways in all locations: Results in 100 consecutive patients
35. Clinical and electrophysiologic characteristics and long-term efficacy of slow-pathway catheter ablation in patients with spontaneous supraventricular tachycardia and dual atrioventricular node pathways without inducible tachycardia
36. Atrioventricular node reentry: Physiology and radiofrequency ablation
37. Catheter ablation for cardiac arrhythmias, personnel, and facilities
38. Catheter ablation for the common type of atrioventricular nodal reentrant tachycardia
39. Evaluation of possible long-term adverse consequences of radiofrequency ablation of accessory pathways
40. Atrioventricular node reentry: Current concepts and new perspectives
41. Evolving concepts in radiofrequency catheter ablation of atrioventricular nodal reentry tachycardia
42. Summary of efficacy and safety of flecainide for supraventricular arrhythmias
43. Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: The United States experience
44. Flecainide acetate for treatment of bypass tract mediated reentrant tachycardia
45. Treatment of paroxysmal supraventricular tachycardia with oral diltiazem
46. Treatment of recurrent paroxysmal ventricular tachycardia
47. A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia
48. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation
49. Oral flecainide, sotalol, and verapamil for the termination of paroxysmal supraventricular tachycardia
50. Long term treatment of paroxysmal cardiac arrhythmias with propranolol
51. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia
52. Intravenous diltiazem for termination of reentrant supraventricular tachycardia: A placebo-controlled, randomized, double-blind, multicenter study
53. Pharmacological management of supraventricular tachycardia
54. Uses of calcium channel blocking agents and beta blocking agents in the control of supraventricular arthythmias
55. Propranolol in cardiac arrhythmias: A comparative study of the conventional and long-acting formulations
56. Long-term low-dose amiodarone therapy in the management of ventricular and supraventricular tachyarrhythmias: Efficacy and safety
57. Episodic drug treatment in the management of paroxysmal arrhythmias
58. Oral verapamil for paroxysmal supraventricular tachycardia: A long-term, double-blind randomized trial
59. Long-term efficacy and safety of flecainide for supraventricular tachycardia
60. Life-table methods for evaluating antiarrhythmic drug efficacy in patients with paroxysmal atrial tachycardia
61. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. A randomized, placebo-controlled, crossover trial in patients tolerating oral therapy
62. Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia
63. Supraventricular tachyarrhythmias: Drug therapy versus catheter ablation
64. Clinical observations on the use of propranolol in disorders of cardiac rhythm
65. Long-term therapy of paroxysmal supraventricular tachycardia: A randomized, double-blind comparison of digoxin, propranolol and verapamil
66. Effects of oral diltiazem in paroxysmal supraventricular tachycardia
67. Radiofrequency catheter ablation versus medical therapy for initial treatment of supraventricular tachycardia and its impact on quality of life and healthcare costs
68. Safety, feasibility and cost of outpatient radiofrequency catheter ablation of accessory atrioventricular connections
69. Markov models in medical decision making: A practical guide
70. Report of the NASPE Policy Conference on antibradycardia pacemaker follow-up: Effectiveness, needs, and resources
71. Current role of pharmacologic therapy for patients with paroxysmal supravenrticular tachycardia
72. An approach to therapy for paroxysmal supraventricular tachycardia
73. Antiarrrhythmic strategies for the chronic management of supraventricular tachycardias
74. Medical decision making: Probabilistic medical reasoning
75. Screening for breast career
76. Screening for cervical cancer
77. Time-tradeoff values and standard-gamble utilities assessed during telephone interviews versus face-to-face interviews